{"id":"https://openalex.org/W4285098112","doi":"https://doi.org/10.2478/prilozi-2022-0026","title":"Comparative, Single-Dose, 2-Way Cross-Over Bioavailability Study of Two Olanzapine 10 Mg Tablet Formulations in Healthy Volunteers Under Fasting Conditions","display_name":"Comparative, Single-Dose, 2-Way Cross-Over Bioavailability Study of Two Olanzapine 10 Mg Tablet Formulations in Healthy Volunteers Under Fasting Conditions","publication_year":2022,"publication_date":"2022-07-01","ids":{"openalex":"https://openalex.org/W4285098112","doi":"https://doi.org/10.2478/prilozi-2022-0026","pmid":"https://pubmed.ncbi.nlm.nih.gov/35843923"},"language":"en","primary_location":{"id":"doi:10.2478/prilozi-2022-0026","doi":"https://doi.org/10.2478/prilozi-2022-0026","is_oa":true,"landing_page_url":"https://doi.org/10.2478/prilozi-2022-0026","pdf_url":"https://sciendo.com/pdf/10.2478/prilozi-2022-0026","source":{"id":"https://openalex.org/S4210199378","display_name":"PRILOZI","issn_l":"0350-1914","issn":["0350-1914","1857-8985","1857-9345","2671-3802"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","medline","poland-20"],"host_organization":"https://openalex.org/P4310313990","host_organization_name":"De Gruyter","host_organization_lineage":["https://openalex.org/P4310313990"],"host_organization_lineage_names":["De Gruyter"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PRILOZI","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://sciendo.com/pdf/10.2478/prilozi-2022-0026","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5049640658","display_name":"Emilija Atanasovska","orcid":"https://orcid.org/0000-0003-4596-9563","observed_orcids":["https://orcid.org/0000-0003-4596-9563"]},"institutions":[{"id":"https://openalex.org/I76245029","display_name":"Ss. Cyril and Methodius University in Skopje","ror":"https://ror.org/02wk2vx54","country_code":"MK","type":"education","lineage":["https://openalex.org/I76245029"]}],"countries":["MK"],"is_corresponding":true,"raw_author_name":"Emilija Atanasovska","raw_affiliation_strings":["Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine , University \u201cSs. Cyril and Methodius\u201d , 50 Divizija 6 , Skopje , Republic of North Macedonia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine , University \u201cSs. Cyril and Methodius\u201d , 50 Divizija 6 , Skopje , Republic of North Macedonia","institution_ids":["https://openalex.org/I76245029"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078119628","display_name":"Krume Jakjovski","orcid":"https://orcid.org/0000-0001-8640-6906","observed_orcids":["https://orcid.org/0000-0001-8640-6906"]},"institutions":[{"id":"https://openalex.org/I76245029","display_name":"Ss. Cyril and Methodius University in Skopje","ror":"https://ror.org/02wk2vx54","country_code":"MK","type":"education","lineage":["https://openalex.org/I76245029"]}],"countries":["MK"],"is_corresponding":false,"raw_author_name":"Krume Jakjovski","raw_affiliation_strings":["Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine , University \u201cSs. Cyril and Methodius\u201d , 50 Divizija 6 , Skopje , Republic of North Macedonia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine , University \u201cSs. Cyril and Methodius\u201d , 50 Divizija 6 , Skopje , Republic of North Macedonia","institution_ids":["https://openalex.org/I76245029"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110317495","display_name":"Kristina Pavlovska","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I76245029","display_name":"Ss. Cyril and Methodius University in Skopje","ror":"https://ror.org/02wk2vx54","country_code":"MK","type":"education","lineage":["https://openalex.org/I76245029"]}],"countries":["MK"],"is_corresponding":false,"raw_author_name":"Kristina Pavlovska","raw_affiliation_strings":["Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine , University \u201cSs. Cyril and Methodius\u201d , 50 Divizija 6 , Skopje , Republic of North Macedonia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine , University \u201cSs. Cyril and Methodius\u201d , 50 Divizija 6 , Skopje , Republic of North Macedonia","institution_ids":["https://openalex.org/I76245029"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074290389","display_name":"Kalina Gjorgjievska","orcid":"https://orcid.org/0000-0001-5750-4398","observed_orcids":["https://orcid.org/0000-0001-5750-4398"]},"institutions":[{"id":"https://openalex.org/I76245029","display_name":"Ss. Cyril and Methodius University in Skopje","ror":"https://ror.org/02wk2vx54","country_code":"MK","type":"education","lineage":["https://openalex.org/I76245029"]}],"countries":["MK"],"is_corresponding":false,"raw_author_name":"Kalina Gjorgjievska","raw_affiliation_strings":["Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine , University \u201cSs. Cyril and Methodius\u201d , 50 Divizija 6 , Skopje , Republic of North Macedonia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine , University \u201cSs. Cyril and Methodius\u201d , 50 Divizija 6 , Skopje , Republic of North Macedonia","institution_ids":["https://openalex.org/I76245029"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113092575","display_name":"Dimche Zafirov","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I76245029","display_name":"Ss. Cyril and Methodius University in Skopje","ror":"https://ror.org/02wk2vx54","country_code":"MK","type":"education","lineage":["https://openalex.org/I76245029"]}],"countries":["MK"],"is_corresponding":false,"raw_author_name":"Dimche Zafirov","raw_affiliation_strings":["Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine , University \u201cSs. Cyril and Methodius\u201d , 50 Divizija 6 , Skopje , Republic of North Macedonia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine , University \u201cSs. Cyril and Methodius\u201d , 50 Divizija 6 , Skopje , Republic of North Macedonia","institution_ids":["https://openalex.org/I76245029"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084272088","display_name":"Dragica Zendelovska","orcid":"https://orcid.org/0000-0003-4675-6340","observed_orcids":["https://orcid.org/0000-0003-4675-6340"]},"institutions":[{"id":"https://openalex.org/I76245029","display_name":"Ss. Cyril and Methodius University in Skopje","ror":"https://ror.org/02wk2vx54","country_code":"MK","type":"education","lineage":["https://openalex.org/I76245029"]}],"countries":["MK"],"is_corresponding":false,"raw_author_name":"Dragica Zendelovska","raw_affiliation_strings":["Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine , University \u201cSs. Cyril and Methodius\u201d , 50 Divizija 6 , Skopje , Republic of North Macedonia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine , University \u201cSs. Cyril and Methodius\u201d , 50 Divizija 6 , Skopje , Republic of North Macedonia","institution_ids":["https://openalex.org/I76245029"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108683281","display_name":"Marija Petrushevska","orcid":"https://orcid.org/0000-0002-3785-1285","observed_orcids":["https://orcid.org/0000-0002-3785-1285"]},"institutions":[{"id":"https://openalex.org/I76245029","display_name":"Ss. Cyril and Methodius University in Skopje","ror":"https://ror.org/02wk2vx54","country_code":"MK","type":"education","lineage":["https://openalex.org/I76245029"]}],"countries":["MK"],"is_corresponding":false,"raw_author_name":"Marija Petrushevska","raw_affiliation_strings":["Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine , University \u201cSs. Cyril and Methodius\u201d , 50 Divizija 6 , Skopje , Republic of North Macedonia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine , University \u201cSs. Cyril and Methodius\u201d , 50 Divizija 6 , Skopje , Republic of North Macedonia","institution_ids":["https://openalex.org/I76245029"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5075569017","display_name":"Nikola Labachevski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I76245029","display_name":"Ss. Cyril and Methodius University in Skopje","ror":"https://ror.org/02wk2vx54","country_code":"MK","type":"education","lineage":["https://openalex.org/I76245029"]}],"countries":["MK"],"is_corresponding":false,"raw_author_name":"Nikola Labachevski","raw_affiliation_strings":["Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine , University \u201cSs. Cyril and Methodius\u201d , 50 Divizija 6 , Skopje , Republic of North Macedonia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine , University \u201cSs. Cyril and Methodius\u201d , 50 Divizija 6 , Skopje , Republic of North Macedonia","institution_ids":["https://openalex.org/I76245029"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5049640658"],"corresponding_institution_ids":["https://openalex.org/I76245029"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"43","issue":"2","first_page":"135","last_page":"143"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.7476000189781189,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.7476000189781189,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.07450000196695328,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.07280000299215317,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/olanzapine","display_name":"olanzapine","score":1.0},{"id":"https://openalex.org/keywords/bioequivalence","display_name":"bioequivalence","score":0.9369999766349792},{"id":"https://openalex.org/keywords/generic-drug-formulation","display_name":"generic drug formulation","score":0.6710000038146973},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8980000019073486},{"id":"https://openalex.org/keywords/atypical-antipsychotics","display_name":"atypical antipsychotics","score":0.8519999980926514},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.4580000042915344},{"id":"https://openalex.org/keywords/bipolar-disorder","display_name":"bipolar disorder","score":0.9490000009536743},{"id":"https://openalex.org/keywords/single-oral-dose","display_name":"single oral dose","score":0.527999997138977},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.6980000138282776}],"concepts":[{"id":"https://openalex.org/C42404028","wikidata":"https://www.wikidata.org/wiki/Q864940","display_name":"Bioequivalence","level":3,"score":0.8730654716491699},{"id":"https://openalex.org/C2776619155","wikidata":"https://www.wikidata.org/wiki/Q201872","display_name":"Olanzapine","level":3,"score":0.8158091306686401},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7636764049530029},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7125198245048523},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.6402684450149536},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.6281635165214539},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.5836775898933411},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.501171350479126},{"id":"https://openalex.org/C2776921671","wikidata":"https://www.wikidata.org/wiki/Q758295","display_name":"Atypical antipsychotic","level":4,"score":0.4845787286758423},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.48302707076072693},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4184831380844116},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.4070590138435364},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3397170305252075},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.25731319189071655},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.12966012954711914}],"mesh":[{"descriptor_ui":"D000077152","descriptor_name":"Olanzapine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005215","descriptor_name":"Fasting","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013607","descriptor_name":"Tablets","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013810","descriptor_name":"Therapeutic Equivalency","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.2478/prilozi-2022-0026","doi":"https://doi.org/10.2478/prilozi-2022-0026","is_oa":true,"landing_page_url":"https://doi.org/10.2478/prilozi-2022-0026","pdf_url":"https://sciendo.com/pdf/10.2478/prilozi-2022-0026","source":{"id":"https://openalex.org/S4210199378","display_name":"PRILOZI","issn_l":"0350-1914","issn":["0350-1914","1857-8985","1857-9345","2671-3802"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","medline","poland-20"],"host_organization":"https://openalex.org/P4310313990","host_organization_name":"De Gruyter","host_organization_lineage":["https://openalex.org/P4310313990"],"host_organization_lineage_names":["De Gruyter"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PRILOZI","raw_type":"journal-article"},{"id":"pmid:35843923","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/35843923","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki)","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.2478/prilozi-2022-0026","doi":"https://doi.org/10.2478/prilozi-2022-0026","is_oa":true,"landing_page_url":"https://doi.org/10.2478/prilozi-2022-0026","pdf_url":"https://sciendo.com/pdf/10.2478/prilozi-2022-0026","source":{"id":"https://openalex.org/S4210199378","display_name":"PRILOZI","issn_l":"0350-1914","issn":["0350-1914","1857-8985","1857-9345","2671-3802"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","medline","poland-20"],"host_organization":"https://openalex.org/P4310313990","host_organization_name":"De Gruyter","host_organization_lineage":["https://openalex.org/P4310313990"],"host_organization_lineage_names":["De Gruyter"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PRILOZI","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4285098112.pdf","grobid_xml":"https://content.openalex.org/works/W4285098112.grobid-xml"},"referenced_works_count":17,"referenced_works":["https://openalex.org/W1984795712","https://openalex.org/W2002826534","https://openalex.org/W2009832071","https://openalex.org/W2019017741","https://openalex.org/W2034127399","https://openalex.org/W2037698344","https://openalex.org/W2077763539","https://openalex.org/W2095106622","https://openalex.org/W2327860389","https://openalex.org/W2582351617","https://openalex.org/W2591070772","https://openalex.org/W2738539736","https://openalex.org/W2902252387","https://openalex.org/W2945761864","https://openalex.org/W2976455186","https://openalex.org/W2979964442","https://openalex.org/W2992654899"],"related_works":["https://openalex.org/W2979964442","https://openalex.org/W2125315038","https://openalex.org/W2336373477","https://openalex.org/W2479112384","https://openalex.org/W2019017741","https://openalex.org/W2034127399","https://openalex.org/W1984795712","https://openalex.org/W3025858633","https://openalex.org/W2327860389","https://openalex.org/W2368770235"],"abstract_inverted_index":{"Abstract":[0],"Objectives":[1],":":[2,88,164,228],"Olanzapine":[3,63,231],"is":[4,9],"an":[5,127,244],"atypical":[6],"antipsychotic":[7],"that":[8],"approved":[10],"across":[11],"Europe,":[12],"the":[13,48,54,77,109,112,161,166,204,207,217,222,235,248],"USA,":[14],"and":[15,25,111,144,156,192,197,242],"in":[16,29,43,69,130],"many":[17],"other":[18],"countries":[19],"for":[20,37,188,203,225],"oral":[21,67],"treatment":[22],"of":[23,47,56,62,105,124,136,174,206,219],"schizophrenia":[24],"acute":[26],"manic":[27],"episodes":[28],"patients":[30],"with":[31,101,121],"bipolar":[32],"disorder":[33],"as":[34,36,75,117],"well":[35,240],"maintenance":[38],"therapy":[39],"to":[40,52,83,234,247],"prevent":[41],"recurrence":[42],"responders.":[44],"The":[45,180,200,229],"objective":[46],"present":[49],"study":[50,90,132,178],"was":[51,91,232,239],"compare":[53],"pharmacokinetics":[55],"two":[57],"10":[58,118],"mg":[59,119],"tablet":[60],"formulations":[61],"following":[64],"a":[65,92,102],"single":[66],"dose":[68],"healthy":[70,168],"volunteers":[71],"under":[72],"fasting":[73,189],"conditions,":[74],"per":[76],"European":[78],"Medicine":[79],"Agency":[80],"(EMA)":[81],"guidelines":[82],"grant":[84],"marketing":[85],"authorization.":[86],"Methods":[87],"This":[89],"randomized,":[93],"open-label,":[94],"two-treatment,":[95],"two-period,":[96],"two-sequences,":[97],"single-dose,":[98],"cross-over":[99],"design":[100],"washout":[103],"period":[104],"14":[106],"days.":[107],"Both":[108],"test":[110],"reference":[113,236,249],"products":[114],"were":[115,140,153,194,215],"administered":[116],"tablets":[120],"240":[122],"mL":[123],"water":[125],"after":[126,148],"overnight":[128],"fast":[129],"each":[131],"period.":[133],"A":[134],"total":[135],"twenty":[137],"blood":[138],"samples":[139],"collected":[141],"before":[142],"dosing":[143],"within":[145,216],"144":[146],"hours":[147],"drug":[149],"administration.":[150],"Adverse":[151],"events":[152],"monitored,":[154],"recorded,":[155],"evaluated":[157],"by":[158],"investigators":[159],"throughout":[160],"study.":[162],"Results":[163],"Of":[165],"24":[167],"adult":[169],"male":[170],"subjects":[171],"enrolled,":[172],"all":[173],"them":[175],"completed":[176],"both":[177],"periods.":[179],"geometric":[181],"mean":[182],"ratio":[183],"90%":[184,201],"confidence":[185],"intervals":[186],"(CI)":[187],"Cmax,":[190],"AUC0-t,":[191],"AUC0-infinity":[193],"94.83-113.71%,":[195],"95.04-105.69%":[196],"95.94-107.00%,":[198],"respectively.":[199],"CI":[202],"ratios":[205],"three":[208],"primary":[209],"pharmacokinetic":[210],"parameters":[211],"(using":[212],"log-transformed":[213],"data)":[214],"range":[218],"80-125%,":[220],"meeting":[221],"regulatory":[223],"criteria":[224],"bioequivalence.":[226],"Conclusions":[227],"generic":[230],"bioequivalent":[233],"formulation.":[237],"It":[238],"tolerated":[241],"provides":[243],"acceptable":[245],"alternative":[246],"drug.":[250]},"counts_by_year":[],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2022-07-14T00:00:00"}